within Pharmacolibrary.Drugs.ATC.N;

model N02AC05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.008333333333333333,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Bezitramide is a potent synthetic opioid analgesic formerly used for the treatment of severe chronic pain. It is a long-acting narcotic and was primarily used as an oral painkiller before it was withdrawn in many countries due to safety concerns, including risk of fatal overdose. It is not currently approved for medical use in most countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult patients based on available secondary sources; no primary pharmacokinetic clinical study published.</p><h4>References</h4><ol><li><p>Meijer, DK, et al., &amp; Wesseling, H (1984). Pharmacokinetics of the oral narcotic analgesic bezitramide and preliminary observations on its effect on experimentally induced pain. <i>European journal of clinical pharmacology</i> 27(5) 615â€“618. DOI:<a href=&quot;https://doi.org/10.1007/BF00556902&quot;>10.1007/BF00556902</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6519169/&quot;>https://pubmed.ncbi.nlm.nih.gov/6519169</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02AC05;
